In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.

Read the full coverage here:

Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer

First-line combination extends PFS in lung cancer subgroup

Pembrolizumab improves outcomes in early-stage resectable lung cancer

Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC

Severe myelosuppression common after chemotherapy for small cell lung cancer

References:

Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738.

Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Press Release

Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles.

Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.